Evidence map›Paper›PMID 30485362›Full record

ArticlePloS one2018

Characterization of the antibacterial activity of Bald's eyesalve against drug resistant Staphylococcus aureus and Pseudomonas aeruginosa.

Amanda L Fuchs, Alan J Weaver, Brian P Tripet, Mary Cloud B Ammons, Martin Teintze, Valérie Copié

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. A case study of the Ancientbiotics collaboration.Patterns (New York, N.Y.) · 2022
    Review
  5. Article
  6. Review
  7. Article
  8. Cells · 2020
    Article
  9. Article
  10. Review
  11. Article
  12. QuantitativeMetabolites · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Amanda L FuchsDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, Montana, United States of America.
Alan J WeaverDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, Montana, United States of America.
Brian P TripetDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, Montana, United States of America.
Mary Cloud B AmmonsDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, Montana, United States of America.ORCID 0000-0002-9717-0844
Martin TeintzeDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, Montana, United States of America.
Valérie CopiéDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, Montana, United States of America.ORCID 0000-0002-2778-1463
Montana State University · US

Funding

The role of the innate immune response in adenovirus Ad14p1 immunopathogenesisP20GM109007 · NIGMS · IDAHO VETERANS RESEARCH / EDUCATION FDN · PI STEVENS, DENNIS L · 2016 to 2021
$10.0M
Acquisition of a 600 MHz NMR cryoprobe and 600 MHz spectrometer console upgradeS10RR026659 · NCRR · MONTANA STATE UNIVERSITY - BOZEMAN · PI COPIE, VALERIE · 2011 to 2011
$600k
Metabolomic Analysis as a Tool to Understanding the Use of Novel Therapeutics in a Host-Pathogen Model of the Chronic Wound EnvironmentK01GM103821 · NIGMS · MONTANA STATE UNIVERSITY - BOZEMAN · PI AMMONS, MARY CLOUD BOSWORTH · 2012 to 2016
$490k
NCRR NIH HHS S10 RR026659NIGMS NIH HHS K01 GM103821NIGMS NIH HHS P20 GM109007
6 · The paper itself

Abstract

Bald's eyesalve is an Anglo-Saxon medicinal remedy that has been used through ancient times to treat eye sty infections and may represent a source of ancientbiotics. This study assessed the efficacy of Bald's eyesalve against several strains of Staphylococcus aureus and Pseudomonas aeruginosa, including a multi-drug resistant phenotype, and identified the principal compound conveying antibacterial activity. Bald's eyesalve formulations were produced by combining garlic, onion or leek, wine, bovine bile, and brass, with specific ingredient omissions in several formulations, followed by incubation at 4 °C for 9 days. Bald's eyesalve formulation ES-GBBr exhibited the greatest antibacterial activity against S. aureus and P. aeruginosa. Fractionation of ES-GBBr using molecular size exclusion and organic solvent partitioning isolated its antibacterial activity to the small molecule nonpolar fraction, and 1D 1H NMR revealed the identity of the antibacterial agent to be allicin. Depletion of allicin from this fraction by addition of exogenous cysteine established that all observable growth inhibition originated from allicin. Quantification of allicin demonstrated that its concentration was significantly greater in ES-GBBr compared to the ES-O formulation; however, this was not due to greater yield. The antibacterial activity of allicin against S. aureus was antagonized by other ingredients within Bald's eyesalve, whereas they were additive or synergistic against P. aeruginosa. These results suggest that neither leek nor onion is necessary for the antibacterial efficacy of Bald's eyesalve against S. aureus or P. aeruginosa, and while allicin was identified as the principal antibacterial agent present, its activity is influenced differentially in the presence of additional Bald's eyesalve ingredients when used against S. aureus compared to P. aeruginosa. Ancientbiotics may provide a source of promising antibacterials; however, identifying the source of activity and assessing distinct formulations for cooperative effects are essential to using ancient remedies, such as Bald's eyesalve, effectively against drug resistant pathogens.

Indexed as

Medicine, TraditionalAnimalsAnti-Bacterial AgentsBileCattleCopperDisulfidesDose-Response Relationship, DrugDrug Resistance, BacterialGarlicMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsOintmentsOnionsPseudomonas aeruginosaSulfinic AcidsallicinAnti-Bacterial AgentsbrassCopperDisulfidesOintmentsSulfinic AcidsZinc

Identifiers

PMID30485362
PMCPMC6261618
OpenAlexW2903550449

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.